Morgan Stanley maintains Vertex (NASDAQ:VERX) with a Underweight and lowers the price target from $18 to $16.
Uncategorized
Morgan Stanley Maintains Underweight on Vertex, Lowers Price Target to $16
Morgan Stanley maintains Vertex (NASDAQ:VERX) with a Underweight and lowers the price target from $18 to $16.
Related Posts
Baudax Bio Announces 1-for-40 Reverse Stock Split
Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the Company's Board of Directors has approved a 1-for-40 reverse stock
